Literature DB >> 11845326

Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic beta-cell lines for use in transplantation.

Oleg G Chepurny1, George G Holz.   

Abstract

To develop transplantable beta-cell lines for the treatment of diabetes mellitus, we have taken advantage of the property of INS-1 cells to synthesize and secrete not only insulin, but also small quantities of the insulinotropic hormone glucagon-like peptide-1 (GLP-1). In INS-1 cells over-expressing the beta-cell GLP-1 receptor (GLP-1-R), we have shown, by radioimmune assay and bioassay of conditioned medium, that an autocrine signaling mechanism of hormone action exists whereby self-secreted GLP-1 acts as a competence factor in support of insulin gene transcription. INS-1 cells also exhibit insulin gene promoter activity, as assayed in cells transfected with a rat insulin gene I promoter-luciferase construct (RIP1-Luc). The GLP-1-R agonist exendin-4 stimulates RIP1-Luc activity in a glucose-dependent manner, an effect mediated by endogenous GLP-1-Rs, and is blocked by the serine/threonine protein kinase inhibitor Ro 31-8220. Over-expression of GLP-1-R in transfected INS-1 cells reduces the threshold for exendin-4 agonist action, whereas basal RIP1-Luc activity increases 2.5-fold in the absence of added agonist. The increase of basal RIP1-Luc activity is a consequence of autocrine stimulation by self-secreted GLP-1 and is blocked by introduction of (1) an inactivating W39A mutation in the N-terminus ligand-binding domain of GLP-1-R or (2) mutations in the third cytoplasmic loop that prevent G protein coupling. No evidence for constitutive ligand-independent signaling properties of the GLP-1-R has been obtained. Over-expression of GLP-1-R increases the potency and efficacy of D-glucose as a stimulator of RIP1-Luc. Thus, INS-1 cells over-expressing the GLP-1-R recapitulate the incretin hormone effect of circulating GLP-1, thereby providing a possible strategy by which beta-cell lines may be engineered for efficient glucose-dependent insulin biosynthesis and secretion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11845326      PMCID: PMC2922114          DOI: 10.1007/s00441-001-0494-7

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  30 in total

Review 1.  The glucagon-like peptides.

Authors:  T J Kieffer; J F Habener
Journal:  Endocr Rev       Date:  1999-12       Impact factor: 19.871

Review 2.  Pancreas and islet transplantation for patients with diabetes.

Authors:  R P Robertson; C Davis; J Larsen; R Stratta; D E Sutherland
Journal:  Diabetes Care       Date:  2000-01       Impact factor: 19.112

Review 3.  Islet and stem cell transplantation for treating diabetes.

Authors:  P Serup; O D Madsen; T Mandrup-Poulsen
Journal:  BMJ       Date:  2001-01-06

4.  Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation.

Authors:  H Wang; P Maechler; B Ritz-Laser; K A Hagenfeldt; H Ishihara; J Philippe; C B Wollheim
Journal:  J Biol Chem       Date:  2001-04-17       Impact factor: 5.157

5.  Proglucagon processing in a rat islet cell line resembles phenotype of intestine rather than pancreas.

Authors:  J Philippe; S Mojsov; D J Drucker; J F Habener
Journal:  Endocrinology       Date:  1986-12       Impact factor: 4.736

6.  Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element.

Authors:  G Skoglund; M A Hussain; G G Holz
Journal:  Diabetes       Date:  2000-07       Impact factor: 9.461

7.  Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells.

Authors:  A M Salapatek; P E MacDonald; H Y Gaisano; M B Wheeler
Journal:  Mol Endocrinol       Date:  1999-08

8.  In vitro cultivation of human islets from expanded ductal tissue.

Authors:  S Bonner-Weir; M Taneja; G C Weir; K Tatarkiewicz; K H Song; A Sharma; J J O'Neil
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

9.  Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion.

Authors:  H E Hohmeier; H Mulder; G Chen; R Henkel-Rieger; M Prentki; C B Newgard
Journal:  Diabetes       Date:  2000-03       Impact factor: 9.461

10.  Constitutive receptor systems for drug discovery.

Authors:  G Chen; C Jayawickreme; J Way; S Armour; K Queen; C Watson; D Ignar; W J Chen; T Kenakin
Journal:  J Pharmacol Toxicol Methods       Date:  1999-12       Impact factor: 1.950

View more
  6 in total

1.  Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells.

Authors:  Guoxin Kang; Jamie W Joseph; Oleg G Chepurny; Marie Monaco; Michael B Wheeler; Johannes L Bos; Frank Schwede; Hans-G Genieser; George G Holz
Journal:  J Biol Chem       Date:  2002-12-20       Impact factor: 5.157

2.  cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic beta cells and rat INS-1 cells.

Authors:  Guoxin Kang; Oleg G Chepurny; Brian Malester; Michael J Rindler; Holger Rehmann; Johannes L Bos; Frank Schwede; William A Coetzee; George G Holz
Journal:  J Physiol       Date:  2006-04-13       Impact factor: 5.182

3.  Enhanced Rap1 activation and insulin secretagogue properties of an acetoxymethyl ester of an Epac-selective cyclic AMP analog in rat INS-1 cells: studies with 8-pCPT-2'-O-Me-cAMP-AM.

Authors:  Oleg G Chepurny; Colin A Leech; Grant G Kelley; Igor Dzhura; Elvira Dzhura; Xiangquan Li; Michael J Rindler; Frank Schwede; Hans G Genieser; George G Holz
Journal:  J Biol Chem       Date:  2009-02-25       Impact factor: 5.157

Review 4.  Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.

Authors:  George G Holz; Oleg G Chepurny
Journal:  Curr Med Chem       Date:  2003-11       Impact factor: 4.530

5.  A cAMP and Ca2+ coincidence detector in support of Ca2+-induced Ca2+ release in mouse pancreatic beta cells.

Authors:  Guoxin Kang; Oleg G Chepurny; Michael J Rindler; Leon Collis; Zina Chepurny; Wen-Hong Li; Mark Harbeck; Michael W Roe; George G Holz
Journal:  J Physiol       Date:  2005-04-28       Impact factor: 5.182

6.  Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist.

Authors:  Wenbo Sai; Hong Tian; Kangmin Yang; Daoqi Tang; Jinxiao Bao; Yang Ge; Xiaoda Song; Yu Zhang; Cheng Luo; Xiangdong Gao; Wenbing Yao
Journal:  Int J Mol Sci       Date:  2017-03-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.